Coverage varies widely by plan and employer
Companion digital solutions can help users develop new behaviors to ensure theyve made a change that will stick for good. Marni Allen, CMO, Bioniq PepsiCo: Negligible impact At PepsiCo, so far at least, the impact of GLP-1 drugs has been negligible, CEO Ramon Laguarta told analysts during the firms latest earnings call
Pricing has shifted dramatically since 2024
JACC 82(9):833955 Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR et al (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
Nevertheless, uncritical enthusiasm is unwarranted given the pervasive heterogeneity of existing trials, the profound dependence of therapeutic effects on formulation characteristics, and the inherent limitations of predominantly short-duration interventions in a disease defined by decades of progressive metabolic deterioration
